Peptide N-methylation is an important strategy used by medicinal chemists to improve cell permeability, oral bioavailability, and target affinity of peptide-based inhibitors. Correspondingly, N-methyl amides appear extensively in bioactive natural products. In the case of the immunosuppressant cyclosporine, for example, specific N-methylation of seven out of ten backbone amide nitrogens in the cyclic decapeptide is thought to allow a conformational ‘shapeshifting’ that hides polar N–H moieties and facilitates passive diffusion across cell membranes. Until now, N-methylation has primarily been the mark of peptide natural products from complex nonribosomal peptide synthetase (NRPS) assembly lines, and has not previously been found among their cousins, the ribosomally synthesized and post-translationally modified peptide (RiPP) natural products. In this issue, van der Velden et al. uncover the biosynthetic origins of the omphalotins, peptide natural products from the bioluminescent fungus O. olearius (Fig. 1a), and bring peptide backbone N-methylation into the realm of peptide post-translational modifications
